The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1643
ISSUE1643
February 7, 2022
Difelikefalin (Korsuva) for Chronic Kidney Disease-Associated Pruritus
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Difelikefalin (Korsuva) for Chronic Kidney Disease-Associated Pruritus
February 7, 2022 (Issue: 1643)
Difelikefalin (Korsuva – Vifor), an IV kappa opioid
receptor (KOR) agonist, has been approved by the
FDA for treatment of moderate to severe pruritus
associated with chronic kidney disease (CKD) in
adults on hemodialysis. It is the first drug...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.